drugset / Trial / NCT00003282

EF5 in Treating Patients With Solid Tumors

NCT00003282

Phase 1 Completed 50 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelDiagnostic

Summary

Diagnostic procedures using the drug EF5 to detect the presence of oxygen in tumor cells may help to plan effective treatment for solid tumors. This phase I trial is studying how well EF5 works in detecting the presence of oxygen in tumor cells in patients with solid tumors that can be biopsied or removed by surgery

Timeline

Start
1998-03
Primary completion
2005-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject EF5 Diagnostic / imaging agent Intravenous